US Food and Drug Administration (FDA) has approved SPEVIGO\u00ae (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing \u226540 kg.<\/p>\n
Generalized pustular psoriasis (GPP) is a rare and potentially-life threatening disease characterized by extensive eruption of pustules on the skin, with or without systemic inflammation and with or without plaque psoriasis.
\nSpesolimab (SPEVIGO) is an IL-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. Spesolimab was given orphan drug designation by the US FDA in October 2018 for the treatment of GPP flares in adults. In December 2021, the US FDA accepted a biologics license application and granted priority review for spesolimab for the treatment of GPP flares; prior to this, spesolimab had been granted breakthrough therapy designation . On 1 September 2022, spesolimab received its first approval in the USA for the treatment of GPP flares in adults.<\/p>\n
If SPEVIGO (spesolimab-sbzo) injection\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> SPEVIGO (spesolimab-sbzo) is used to treat a severe form of psoriasis (generalized pustular psoriasis)<\/b>. Spesolimab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-36) that may cause inflammation and swelling.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"SPEVIGO (spesolimab-sbzo) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2022<\/h2>\n